Glenmede Trust CO Na Dexcom Inc Transaction History

Glenmede Trust CO Na

$20.6 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$110.31 - $140.45 $96,962 - $123,455	879 Added 21.04%	5,056 $573,000
Q1 2024 May 15, 2024	BUY	$114.22 - $140.1 $49,343 - $60,523	432 Added 11.54%	4,177 $579,000
Q4 2023 Feb 13, 2024	SELL	$75.49 - $124.16 $96,174 - $158,179	-1,274 Reduced 25.38%	3,745 $464,000
Q3 2023 Nov 14, 2023	SELL	$86.06 - $137.93 $10,241 - $16,413	-119 Reduced 2.32%	5,019 $468,000
Q1 2023 May 15, 2023	BUY	$104.0 - $122.92 $77,688 - $91,821	747 Added 17.01%	5,138 $596,000
Q4 2022 Feb 14, 2023	BUY	$84.98 - $122.67 $2,974 - $4,293	35 Added 0.8%	4,391 $497,000
Q3 2022 Nov 16, 2022	BUY	$76.35 - $94.18 $332,580 - $410,248	4,356 New	4,356 $350,000
Q4 2020 Feb 16, 2021	SELL	$78.0 - $104.5 $12,324 - $16,511	-158 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$95.51 - $112.95 $8,595 - $10,165	-90 Reduced 36.29%	158 $65,000
Q2 2020 Aug 14, 2020	BUY	$62.68 - $105.34 $11,971 - $20,119	191 Added 335.09%	248 $99,000
Q4 2019 Feb 12, 2020	SELL	$36.62 - $57.29 $4,504 - $7,046	-123 Reduced 68.33%	57 $12,000
Q3 2019 Nov 14, 2019	BUY	$35.53 - $43.8 $2,984 - $3,679	84 Added 87.5%	180 $26,000
Q1 2019 May 14, 2019	SELL	$28.07 - $38.18 $112 - $152	-4 Reduced 4.0%	96 $11,000
Q4 2018 Feb 14, 2019	BUY	$26.99 - $37.37 $1,835 - $2,541	68 Added 212.5%	100 $11,000
Q3 2018 Nov 15, 2018	SELL	$23.35 - $36.72 $373 - $587	-16 Reduced 33.33%	32 $4,000
Q2 2018 Aug 15, 2018	SELL	$17.54 - $25.22 $719 - $1,034	-41 Reduced 46.07%	48 $5,000
Q4 2017 Feb 15, 2018	SELL	$11.12 - $15.38 $411 - $569	-37 Reduced 29.37%	89 $5,000
Q3 2017 Nov 14, 2017	BUY	$11.36 - $18.98 $1,431 - $2,391	126	126 $0

Others Institutions Holding DXCM

# of Institutions

1,014

Shares Held

351M

Call Options Held

5.51M

Put Options Held

5.6M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

News

Stay updated on Glenmede Trust CO Na with notifications on news.

Account